Biochem/physiol Actions

In hemodialysis patients increased plasma levels of MR-pro-ADM (mid-regional-pro-adrenomedullin) is linked with decreased survival. This is due to increased vasodilation in response to higher levels of MR-pro-ADM; lower levels of this peptide result in increased vasoconstriction and hence, better prognosis. This peptide is also associated with increased cardiovascular mortality in dialysis patients. In type II diabetic patients, MR-pro-ADM peptide is linked with renal outcome, as adrenomedullin (ADM) gene regulates susceptibility to nephropathic progression.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

MR-pro-ADM (mid-regional-pro-adrenomedullin) is a 47-residue long peptide, produced during posttranslational processing of adrenomedullin. It has a molecular weight of 5.1kDa. Adrenomedullin (ADM) is a vasodilator peptide, which is produced and released by a wide variety of cells such as, macrophages, fibroblasts, cardiomyocytes etc. MR-pro-ADM functions as a substitute marker for ADM. This peptide is coded by the gene localized to human chromosome 11p15.4, which is composed of four exons and three introns.

Immunogen

a synthetic peptide corresponding to the internal region of human Adrenomedullin (ADM) , conjugated to KLH.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.